Last reviewed · How we verify
control dendritic cells
At a glance
| Generic name | control dendritic cells |
|---|---|
| Sponsor | University of Pittsburgh |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Seizure
- Lymphopenia
- Neurology - Other
- Hypertension
- Diarrhea
- CD4 Count
- Neutrophils/granulocytes
- Platelets
- Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils
- Infection - Other
- Opportunistic infection associated with >=Grade 2 Lymphopenia
- Sodium, serum-low (hyponatremia)
Key clinical trials
- IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma (PHASE1)
- Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease (NA)
- Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma (PHASE3)
- Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma (PHASE2)
- A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis (PHASE2)
- Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer (PHASE2)
- Immune Cell Therapy for Advanced Solid Tumors (PHASE1, PHASE2)
- Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- control dendritic cells CI brief — competitive landscape report
- control dendritic cells updates RSS · CI watch RSS
- University of Pittsburgh portfolio CI